Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah- Tikvah, Israel.
Blood Cancer J. 2021 Dec 7;11(12):196. doi: 10.1038/s41408-021-00592-3.
Belantamab mafodotin is a highly selective targeted therapy for multiple myeloma. It targets the B cell maturation antigen (BCMA) on plasma cells and showed promising results in several randomized clinical trials. We report the outcomes of 36 patients treated at Mayo Clinic. Our cohort received a median of eight prior lines of therapy. Six patients received belantamab in combination with other medications (pomalidomide, cyclophosphamide, thalidomide), 13 patients (36%) were 70 years or older, two patients had a creatinine of >2.5 mg/dL, and one patient was on dialysis. All three patients with renal failure received full dose belantamab. Chimeric antigen receptor (CAR-T) therapy was used prior to belantamab in seven patients and none of them responded to belantamab therapy. The overall response rate (ORR) was 33% (CR 6%, VGPR 8%, PR 19%), like the ORR reported in the DREAMM-2 trial. Keratopathy developed in 16 patients (43%), grade 1 in six patients, grade 2 in seven patients, and grade 3 in three patients. Eight percent discontinued therapy due to keratopathy. The median PFS and OS was 2 months and 6.5 months, respectively.
贝兰他单抗马妥昔单抗是一种针对多发性骨髓瘤的高度选择性靶向治疗药物。它针对浆细胞上的 B 细胞成熟抗原 (BCMA)，并在几项随机临床试验中显示出良好的效果。我们报告了在 Mayo 诊所接受治疗的 36 名患者的结果。我们的队列接受了中位数为 8 线的治疗。6 名患者接受了贝兰他单抗联合其他药物（泊马度胺、环磷酰胺、沙利度胺）治疗，13 名患者（36%）年龄在 70 岁或以上，2 名患者的肌酐>2.5mg/dL，1 名患者正在接受透析。所有 3 名肾功能衰竭患者均接受了全剂量贝兰他单抗治疗。在接受贝兰他单抗治疗之前，有 7 名患者接受了嵌合抗原受体 (CAR-T) 治疗，他们均未对贝兰他单抗治疗产生反应。总缓解率（ORR）为 33%（完全缓解率 6%，非常好的部分缓解率 8%，部分缓解率 19%），与 DREAMM-2 试验报告的 ORR 相似。16 名患者（43%）出现角膜病，6 名患者为 1 级，7 名患者为 2 级，3 名患者为 3 级。8%的患者因角膜病停止治疗。中位无进展生存期和总生存期分别为 2 个月和 6.5 个月。
